Most cited papers from Sarcoma Oncology Center

Sarcoma Oncology Center

What are the most cited papers from Sarcoma Oncology Center?

The most cited paper from Sarcoma Oncology Center is "Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial" (Winette T.A. van der Graaf et al., 2012), with 2,123 citations. Next come "Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials" (1,802) and "Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial" (782).

Published TypeFieldAccessCitations

Showing 50 of 60 papers. Every paper with more than 144 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial Winette T.A. van der Graaf et al. · The Lancet Open access	May 2012	2,123
2	Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials Robert Charles Doebele et al. · The Lancet Oncology Open access	11 Dec 2019	1,802
3	Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial Patrick Schöffski, Sant P. Chawla, Robert G. Maki et al. · The Lancet Open access	12 Feb 2016	782
4	Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion Sewa S. Legha, Robert S. Benjamin, Bruce R. MacKay et al. · Annals of Internal Medicine	Feb 1982	769
5	Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study David Morgan Thomas, Robert Mikael Henshaw, Keith M. Skubitz et al. · The Lancet Oncology	11 Feb 2010	716
6	Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. John A. Glaspy, Ronald Bukowski, Douglas Steinberg et al. · Journal of Clinical Oncology	Mar 1997	706
7	Interleukin-6 signaling pathway in targeted therapy for cancer Yuqi Guo, Feng Xu, Tianjian Lu et al. · Cancer Treatment Reviews	29 May 2012	697
8	Histologic Subtype and Margin of Resection Predict Pattern of Recurrence and Survival for Retroperitoneal Liposarcoma Samuel Singer, Cristina R. Antonescu, Elyn Riedel et al. · Annals of Surgery Open access	Sep 2003	675
9	Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study Sant P. Chawla, Robert Mikael Henshaw, Leanne L. Seeger et al. · The Lancet Oncology	15 Jul 2013	589
10	Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Alan N. Houghton, David M. Mintzer, Carlos Cordon‐Cardo et al. · Proceedings of the National Academy of Sciences Open access	Feb 1985	568
11	Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial José Manuel Trigo et al. · The Lancet Oncology	27 Mar 2020	488
12	Microsatellite instability in the insulin–like growth factor II receptor gene in gastrointestinal tumours Rhonda Frances Souza et al. · Nature Genetics	Nov 1996	449
13	Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone Daniel G. Branstetter, Scott D. Nelson, Juan Carlos Manivel et al. · Clinical Cancer Research	18 Jun 2012	430
14	A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors Lei L. Chen et al. · Cancer Research	Sep 2004	342
15	Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial Michael Charles Heinrich et al. · The Lancet Oncology	29 Jun 2020	321
16	Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial William D. Tap et al. · The Lancet Oncology Open access	24 Jun 2017	314
17	Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma Michael David Jain et al. · Blood Open access	15 Jan 2021	307
18	Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients Giorgio Parmiani, Chiara Castelli, Lorenzo Pilla et al. · Annals of Oncology Open access	21 Nov 2006	305
19	Aurora Kinases: New Targets for Cancer Therapy Richard D. Carvajal, Archie N. Tse, Gary K. Schwartz · Clinical Cancer Research Open access	Dec 2006	275
20	Adriamycin (NSC 123127) cardiomyopathy. An overview with determination of risk factors Robert A. Minow, Robert S. Benjamin, Jeffrey A. Gottlieb	1975	274
21	Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma Lara Emily Davis, Vanessa Bolejack, Christopher W. Ryan et al. · Journal of Clinical Oncology Open access	23 Apr 2019	272
22	Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors Mrinal M. Gounder et al. · New England Journal of Medicine Open access	8 Mar 2023	270
23	High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. SHREYASKUMAR R. PATEL, Saroj Vadhan‐Raj, Nicholas Papadopolous et al. · Journal of Clinical Oncology	Jun 1997	258
24	Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study Sant P. Chawla, Jean‐Yves Blay, Piotr Lukasz Rutkowski et al. · The Lancet Oncology	5 Nov 2019	257
25	Diagnostic Utility of p16, CDK4, and MDM2 as an Immunohistochemical Panel in Distinguishing Well-differentiated and Dedifferentiated Liposarcomas From Other Adipocytic Tumors Khin Thway, Rashpal Flora, Chirag M. Shah et al. · The American Journal of Surgical Pathology	7 Feb 2012	253
26	Gene Expression Profiling of Liposarcoma Identifies Distinct Biological Types/Subtypes and Potential Therapeutic Targets in Well-Differentiated and Dedifferentiated Liposarcoma Samuel Singer, Nicholas D. Socci, Grazia Ambrosini et al. · Cancer Research Open access	15 Jul 2007	252
27	A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. Michael S. Ewer, Mohammed K. Ali, Brendan J. MacKay et al. · Journal of Clinical Oncology	Feb 1984	244
28	Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical Model Rashmi K Chugh, J. Kyle Wathen, Robert G. Maki et al. · Journal of Clinical Oncology	19 May 2009	236
29	Biphasic metaplastic sarcomatoid carcinoma of the breast Bryan T. Hennessy, Sharon Hermes Giordano, Kristine R. Broglio et al. · Annals of Oncology Open access	9 Feb 2006	224
30	Stimulation of Megakaryocyte and Platelet Production by a Single Dose of Recombinant Human Thrombopoietin in Patients with Cancer Saroj Vadhan‐Raj, Lesley J. Murray, Carlos Bueso-Ramos et al. · Annals of Internal Medicine	May 1997	224
31	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors George D. Demetri et al. · Clinical Cancer Research Open access	10 Feb 2022	222
32	Adult rhabdomyosarcoma Darren J. Little, Matthew T. Ballo, Gunar K. Zagars et al. · Cancer Open access	11 Jul 2002	217
33	Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST) Anu Gupta, Srirupa Roy, Alexander J. Lazar et al. · Proceedings of the National Academy of Sciences Open access	26 Jul 2010	217
34	Novel strategies to prevent the development of multidrug resistance (MDR) in cancer Jinglu Wang, Nicole A. Seebacher, Huirong Shi et al. · Oncotarget Open access	12 Jul 2017	211
35	Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma Mrinal M. Gounder et al. · Nature Communications Open access	15 Jun 2022	204
36	A phase 2 trial of R1507, a monoclonal antibody to the insulin‐like growth factor‐1 receptor (IGF‐1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study Alberto S. Pappo, Gilles Vassal, John J. Crowley et al. · Cancer Open access	2 May 2014	204
37	Programmed Cell Death Ligand 1 Expression in Osteosarcoma Jacson K. Shen, Gregory Michael Cote, Edwin Choy et al. · Cancer Immunology Research Open access	21 Apr 2014	201
38	Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. David J. Stewart, Milam E. Leavens, Moshe H Maor et al. · PubMed	Jun 1982	195
39	Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts Silvia Stacchiotti et al. · ESMO Open Open access	Jun 2021	192
40	A Synovial Sarcoma-Specific Preoperative Nomogram Supports a Survival Benefit to Ifosfamide-Based Chemotherapy and Improves Risk Stratification for Patients Robert J. Canter, Li-Xuan Qin, Robert G. Maki et al. · Clinical Cancer Research Open access	15 Dec 2008	186
41	nab -Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors Andrew J. Wagner, Vinod Ravi, Richard F. Riedel et al. · Journal of Clinical Oncology Open access	12 Oct 2021	184
42	Feasibility and Safety of En Bloc Resection for Primary Spine Tumors Tomasato Yamazaki, Gregory S. McLoughlin, Shreyaskuma Patel et al. · Spine	Oct 2009	179
43	Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas Nathan D. Price, Jonathan C. Trent, Adel K. El‐Naggar et al. · Proceedings of the National Academy of Sciences Open access	21 Feb 2007	176
44	Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid‐type fibromatosis by whole‐exome sequencing and genomic analysis Aimee Marie Crago, Juliann Chmielecki, Mara W. Rosenberg et al. · Genes Chromosomes and Cancer Open access	14 Jul 2015	171
45	Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long? Emanuela Palmerini, Neal Shiv Chawla, Stefano A. Ferrari et al. · European Journal of Cancer	17 Mar 2017	168
46	Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma Michiro Susa, Arun K. Iyer, Keinosuke Ryu et al. · BMC Cancer Open access	16 Nov 2009	164
47	Malignant Peripheral Nerve Sheath Tumor Aaron Watkins James, Elizabeth Shurell, Arun S. Singh et al. · Surgical Oncology Clinics of North America	2 Sep 2016	161
48	An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic Ariel Fernández, Angela M. Sanguino, Zhenghong Peng et al. · Journal of Clinical Investigation Open access	3 Dec 2007	161
49	Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients Stephen T. Sonis, Nathaniel Simon Treister, Sant P. Chawla et al. · Cancer Open access	27 Oct 2009	161
50	Definition of pRB- and p53-Dependent and -Independent Steps in HIRA/ASF1a-Mediated Formation of Senescence-Associated Heterochromatin Foci Xiaofen Ye, Brad J. Zerlanko, Rugang Zhang et al. · Molecular and Cellular Biology Open access	23 Jan 2007	158

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.